General information
CureVac SE
Friedrich-Miescher-Str. 15
72076 Tübingen, Baden-Württemberg
Germany
Contact person: Sarah Fakih, Vice President, Corporate Communications & IR
Company main phone: +49 (70) 7198830
Website: https://www.curevac.com
Year founded: | 2000
|
Source of foundation: | Spin-off from university |
Name of foundation source: | University of Tuebingen |
No. of employees: |
Worldwide: 825 |
Corporate description / mission:
CureVac is a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”). The company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases.
State of ownership: Private / independent
Headquarters: HQ: Yes
IPO (year): 2020
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Anti-infectives
- Antibodies
- Drug delivery
- Immunotherapy
- Nucleic acid drugs
- Vaccines
|
Primary therapeutic areas: |
- Digestive system / gastroenterology
- Diseases of the eye / ophthalmology
- Infectious and parasitic diseases / infectiology / parasitology
- Neoplasms / cancer / oncology
- Respiratory / pulmonology
|
Business model: |
- In-licensing
- Out-licensing
- R&D
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 6 | |
Phase I: | 5 | |
Phase II: | 5 | |
Description of products:
Seasonal Influenza vaccine candidate - B strain optimization (Modified mRNA)
Seasonal Influenza vaccine candidates (Modified mRNA)
Avian Influenza (H5N1)
FLU SV mRNA, etc.
Special IP situation:
The company currently has approximately 800 granted patents.
Technology used:
RNActive®
RNArt®
RNAntibody®
RNAdjuvant®
Financing details
Fiscal year (end of) 2024
Revenues: | USD 560.28M | |
R&D expenses: | USD 160.21M | |
Net earnings: | USD 169.79M | |
Cash: | USD 504.34M | |
Total liabilities: | USD 111.20M | |
No. of shares: | 225'159'008 | |
Market cap. / valuation: | USD 1'254.14M | |
Collaborations & Clients
Partnering strategy / collaborations:
The University of Texas MD Anderson Cancer Center
Bill & Melinda Gates Foundation
CRISPR Therapeutics, etc.